ChemicalBook Product Catalog API Antineoplastic agents Other antineoplastic Drugs Faricimab

Faricimab

Product NameFaricimab
CAS1607793-29-2
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO)[1][2][3][4][5].

in vivo

Faricimab (10 mg/kg, i.p., twice interval 1 week for 1 or 5 weeks) reduces spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1⁺, CD11b⁺, and CD45⁺ cell infiltration in JR5558 mice^[4].
Faricimab (3 μg/μL, intravitreal injections, a single dose for 48 h) prevents ischemia/reperfusion (I/R) injury-induced retinal permeability and cell death in retinal I/R injury mouse model^[4].

Animal Model:	Retinal I/R injury mouse model^[4]
Dosage:	3 μg/μL
Administration:	intravitreal injections, a single dose for 48 h
Result:	Significantly reduced retinal vascular permeability (by 64%) and cell death compared with IgG control-treated mice.

Animal Model:	JR5558 mice^[4]
Dosage:	10 mg/kg
Administration:	i.p., twice interval 1 week for 1 or 5 weeks
Result:	Might promote vascular stability by inhibiting neovascularization and subsequent neovascular leakage and decreased immune cell accumulation associated with sCNV lesions in JR5558 mice.

References

[1] Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170. DOI:10.1016/j.ophtha.2019.03.023
[2] Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DOI:10.1080/13543784.2021.1879791
[3] Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5. DOI:10.1186/s40942-024-00525-9
[4] Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464. DOI:10.3389/fncel.2023.1192464
[5] Jrstad K, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65. DOI:10.1186/s40942-023-00507-3

Faricimab Supplier

Related Product Information

Send Inquriy